Organizations Filed Purposes:
TO PROMOTE AND FOSTER ADVANCES IN TRANSPLANTATION THRU ACTIVITIES THAT HAVE INCLUDED PARTICIPATION IN CLINICAL TRIALS INVESTIGATING DIFFERENT IMMUNOSUPPRESSIVE REGIMENS, DEVELOPMENT OF CLINICAL PATHWAYS TO ENHANCE PATIENT CARE, FORUMS FOR PUBLIC AND PHYSICIAN EDUCATION IN TRANSPLANTA- TION, STUDIES RELATED TO OUTCOMES RESEARCH, LABORATORY WORK IN IMMUNOBIOLOGY AND NEW CONCEPTS IN DIABETES MANAGEMENT.
1.BRISTOL-MYERS SQUIBB PROTOCOL IM103-116: "EVALUATION OF THE BENEFITS AND RISKS IN MAINTENANCE RENAL TRANSPLANT RECIPIENTS FOLLOWING CONVERSION TO NULOJIX (BELATACEPT)-BASED IMMUNOSUPPRESSION-; PRINCIPAL INVESTIGATOR: HAROLD YANG MD PHD; JUNE 2013-STUDY COMPLETED IN 2019. 2.BRISTOL-MYERS SQUIBB PROTOCOL IM103-177: "EVALUATION OF ACUTE REJECTION RATES IN DE NOVO RENAL TRANSPLANT RECIPIENTS FOLLOWING THYMOGLOBULIN INDUCTION, CNI-FREE, NULOJIX (BELATACEPT)-BASED IMMUNOSUPPRESSION-; PRINCIPAL INVESTIGATOR: HAROLD YANG MD PHD; APRIL 2014-STUDY COMPLETED IN 2019. 3.NOVARTIS PROTOCOL CRAD001A2433: A 24 MONTH, MULTICENTER, RANDOMIZED, OPEN-LABEL SAFETY AND EFFICACY STUDY OF CONCENTRATION-CONTROLLED EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITOR VS.MYCOPHENOLATE WITH STANDARD CALCINEURIN INHIBITOR IN DE NOVO RENAL TRANSPLANTATION- ADVANCING RENAL TRANSPLANT EFFICACY AND SAFETY OUTCOMES WITH AN EVEROLIMUS-BASED REGIMEN (TRANSFORM); PRINCIPAL INVESTIGATOR: MARY WAYBILL MD; APRIL 2014- STUDY COMPLETED IN 2019. 4. ALBERTA TRANSPLANT APPLIED GENOMICS CENTRE:DIAGNOSTIC AND THERAPEUTIC APPLICATIONS OF MICROAARAYS IN ORGAN TRANSPLANTATION AND NATIVE ORGAN DISEASES: USING MICROARRAYS TO ASSESS TRANSPLANT BIOPSIES: THE FUTURE STANDARD OF CARE (INTERCOMEX: THE INTERCOM EXTENSION STUDY); SEPTEMBER 2015-STUDY COMPLETED IN 2019. 5.ASTELLAS7163-CL-3201:"A PHASE 2A, RANDOMIZED, OPEN-LABEL, ACTIVE CONTROL, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF BLESELUMAB IN PREVENTING THE RECURRENCE OF FOCAL SEGMENTAL GLOMERULOSCEROSIS IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS-; FEBRUARY 2017-PRESENT. STUDY ACTIVE. 6. VITAERIS PROTOCOL VKTX01 "A PIVOTAL PHASE 3 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF CLAZAKIZUMAB FOR THE TREATMENT OF CHRONIC ACTIVE-MEDICATED REJECTION IN KIDNEY TRANSPLANT RECIPIENTS". APRIL 2019-PRESENT. 7. USE OF HEPATITIS C POSITIVE DECEASED DONOR KIDNEYS FOR TRANSPLANTATION IN PATIENTS THAT ARE HEPATITIS C NEGATIVE; SEPTEMBER 2019-PRESENT. 8. EVALUATION OF POST-TRANSPLANT MALIGNANCIES: A RETROSPECTIVE ANALYSIS OF UPMC PINNACLE TRANSPLANT PATIENTS UNDERGOING RENAL TRANSPLANT 200-2019 WHO DEVELOPED MALIGNANCIES. 9. EVALUATION OF POST-OPERATIVE OPIATE PAIN MEDICATIONS (IV>PO) IN LIVING KIDNEY DONORS IS ASSOCIATED WITH INCREASED LENGTH-OF-STAY. "A RETROSPECTIVE ANALYSIS OF PATIENTS UNDERGOING LIVING DONOR NEPHRECTOMY AT UPMC PINNACLE FROM JANUARY 2014 TO MARCH 2020. 10. EFFECT OF INDUCTION AND MYCOPHENOLIC-ACID THERAPEUTIC DRUG MONITORING ON DEVELOPMENT OF LEUKOPENIA FOLLOWING KIDNEY TRANSPLANTATION. "A RETROSPECTIVE CHART REVIEW OF ADULT RENAL TRANSPLANT PATIENTS AT UPMC PINNACLE FROM MARCH 2016 TO MARCH 2019.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Mary M Waybill | PHYSICIAN | 0 | $0 |
| Harold C Yang Md | PRESIDENT | 0 | $0 |
| Jonathan R Diamond | DIRECTOR | 0 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202041789349300439_public.xml